65,437 trials
Morbid Obesity
Primary: Number of Participants With Postoperative Gastrointestinal Hemorrhage — 13; 39 participants
Hypercholesterolemia · Statin-Associated Myopathy
Primary: Withdrawal of Therapy Due to Muscle Symptoms That Are Either Intolerable and/or Associated With a Creatine Kinase(CK) >500 — 2; 1 Participants
Crohn's Disease
Primary: Mean Change From Baseline in CDEIS (Crohn's Disease Endoscopic Index of Severity) Score at Week 10 Using Local Non-blinded Assessments — -6.47 score on a scale
Hypercholesterolemia or Combined Dyslipidemia
Primary: Percent Change From Baseline in LDL-C — -31.43; -22.41; -38.99; -28.83 Percent change
Articular Cartilage Lesion of the Femoral Condyle
Primary: Histomorphometry Safranin-O + Anti-Collagen II Antibody Staining — 1.01; 0.75 Ratio — p=0.003
Type II Diabetes Mellitus · Dyslipidemia
Primary: NCEP LDL-C Target Attainment — 110; 55 Participants
Cerebral Infarction
Primary: Aspirin Resistance (ARU ≥ 550) — 9; 11 participants — p=0.654
Hypercholesterolemia · Dyslipidemia
Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) — -42.89 percent change
COPD
Primary: Change From Baseline in Post-dose Forced Expiratory Volume in 1 Second After 8 Weeks — 0.29 liters
Perennial Allergic Rhinitis
Primary: Change From Baseline in 12-hour Reflective Total Nasal Symptom Score (AM and PM Combined) at 28 Days. — 14.7; 15.5; 15.8; -3.1 Scores on a Scale — p=0.03
ADHD
Primary: Systolic Blood Pressure — 113.4; 113.0; 115.3; 115.9 mmHg
Rhinitis, Allergic, Perennial
Primary: Comparison of Mean Change From Baseline in Daily Reflective Total Nasal Symptom Score (rTNSS) Over Each Treatment Period of Active Drug Nasal Sprays Versus Placebos…
Perennial Allergic Rhinitis
Primary: Change From Baseline on Direct Visual Nasal Exams to 12 Months — 466; 237; 456; 229 Participants
Nasolabial Folds
Primary: Pain Score Using a 10-cm Visual Analog Pain Scale (1 = no Pain, 10 = Very Severe Pain) — 2.8; 6.6 cm
Anus Neoplasms
Primary: Willingness to Receive the Human Papillomavirus (HPV) Vaccine — 338 Participants